BRAF and beyond: Tailoring strategies for the individual melanoma patient

Journal of Carcinogenesis

Volumn 13, Issue 1, 2014, Pages

  Jarkowski, Anthony ^a   Khushalani, Nikhil ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

BRAF; immunotherapy; MEK; melanoma

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DOVITINIB; IMATINIB; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NIVOLUMAB; PEMBROLIZUMAB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B; TEMSIROLIMUS; TRAMETINIB; VASCULOTROPIN; VEMURAFENIB;

ARTICLE; B RAF KINASE GENE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 GENE; GENE MUTATION; HUMAN; MAMMALIAN TARGET OF RAPAMYCIN GENE; METASTATIC MELANOMA; MITOGEN ACTIVATED PROTEIN KINASE GENE; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; ONCOGENE C KIT; ONCOGENE N RAS; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATIDYLINOSITOL 3 KINASE GENE; PROGRAMMED DEATH 1 RECEPTOR GENE; PROTEIN KINASE B GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; VASCULOTROPIN GENE;

EID: 84906674763     PISSN: 09746773     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.126759     Document Type: Article

References (34)

1. Jung KO, Park SY, Park KY. Longer aging time increases the anticancer and antimetastatic properties of doenjang. Nutrition 2006;22:539-45.
2. Park KY, Jung KO, Rhee SH, Choi YH. Antimutagenic effects of doenjang (Korean fermented soypaste) and its active compounds. Mutat Res 2003;523-524:43-53.
3. Park SK, Seo KI, Choi SH. Quality assessment of commercial doenjang prepared by traditional method. J Korean Soc Food Sci Nutr 2000;9:211-7.
4. Choi YH, Choi BT, Lee WH, Rhee SH, Park KY. Doenjang hexane fraction-induced G1 arrest is associated with the inhibition of pRB phosphorylation and induction of Cdk inhibitor p21 in human breast carcinoma MCF-7 cells. Oncol Rep 2001;8:1091-6.
5. Kim DH, Lee KH, Yook HS, Kim JH, Shin MG, Byun MW. Quality characteristics of gamma irradiated grain shape improved meju. Korean J Food Sci Technol 2000;32:640-5.
6. Ko BK, Kim KM, Hong YS, Lee CH. Metabolomic assessment of fermentative capability of soybean starter treated with high pressure. J Agric Food Chem 2010;58:8738-47.
7. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-17.
8. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: Implications for carcinogenesis and prevention. Gut 1994;35:950-4.
9. Greenwald P, Milner JA, Anderson DE, McDonald SS. Micronutrients in cancer chemoprevention. Cancer Metastasis Rev 2002;21:217-30.
10. Gescher AJ, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: A tale of failure and promise. Lancet Oncol 2001;2:371-9.
11. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011;4:354-64.
12. Müller-Decker K, Fürstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 2007;46:705-10.
13. Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 2006;387:365-72.
14. Danuta MG, Natalia T. Molecular mechanisms of carcinogenesis. In: Wanda BD, editor. Carcinogenesis and Anticarcinogenic Food Components. FL, USA: CRC press; 2006. p. 13-36.
15. Jeong JK. Improvement of quality and probiotic effect of meju and doenjang prepared with mixed starter cultures. Doctoral Thesis. Busan, Korea: Pusan National University; 2012.
16. Jeong JK, Chang HK, Park KY. Inhibitory effects of meju prepared with mixed starter cultures on azoxymethane and dextran sulfate sodium-induced colon carcinogenesis in mice. J Carcinog 2012;11:30-38.
17. Kanneganti M, Mino-Kenudson M, Mizoguchi E. Animal models of colitisassociated carcinogenesis. J Biomed Biotechnol 2011; doi: 10. 11 55 /2011 / 342637.
18. Melgar S, Karlsson L, Rehnström E, Karlsson A, Utkovic H, Jansson L, et al. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int Immunopharmacol 2008;8:836-44.
19. Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S, et al. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 1998;78:986-92.
20. Li H, Wu WK, Li ZJ, Chan KM, Wong CC, Ye CG, et al. 2,3',4,4',5'- Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice. Br J Pharmacol 2010;160:1352-61
21. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79-94.
22. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001;281:R1264-73.
23. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998;114:385-91.
24. Narayanan BA, Narayanan NK, Simi B, Reddy BS. Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res 2003;63:972-9.
25. Elder DJ, Baker JA, Banu NA, Moorghen M, Paraskeva C. Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol 2002;198:428-34.
26. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30:377-86.
27. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001;2:149-56.
28. Felley-Bosco E. Role of nitric oxide in genotoxicity: Implication for carcinogenesis. Cancer Metastasis Rev 1998;17:25-37.
29. Guo XZ, Shao XD, Liu MP, Xu JH, Ren LN, Zhao JJ, et al. Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma. World J Gastroenterol 2002;8:1059-62.
30. Que FG, Gores GJ. Cell death by apoptosis: Basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996;110:1238-43.
31. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
32. Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al. Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999;17:1364-74.
33. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008;14:378-89.
34. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030-40.